GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...

GSK has shifted towards a global marketing model ... Richardson noted that the streaming service has around nine different promotional photos for each programme – and an algorithm picks the ...

GSK said in the new cases that its patents cover technology pioneered in 2008 that provides "the foundation for Moderna's ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GSK and other drugmakers have lost no time in ... the UK’s voluntary scheme that covers branded medicines pricing and access. The pharma industry's challenge to Medicare drug price negotiation ...

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... of 15% for Vaccines, and I'll cover this in more detail in a minute.

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 ...